Trial Profile

A Multicenter Phase II Study of RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive High-risk Non-muscle-invasive Bladder Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Disitamab vedotin (Primary)
Indications Bladder cancer; Carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Jun 2024 According to RemeGen media release, data from this trial presented at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
22 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com